Background Current sampling for total homocysteine (tHcy) is problematic, requiring plasma separation within 15 min. The aim of this study was to develop a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the measurement of tHcy in plasma and dried blood spots and to determine whether the dried blood spot concentration could be used to predict plasma concentrations of tHcy.
Introduction
Reviews of plasma homocysteine measurement 1 and its role as an arteriovascular risk factor 2 have recently appeared in this journal. It is clear that an increase in plasma total homocysteine (tHcy) is associated with an increased risk of arteriovascular disease. 2 If it is found that plasma tHcy is an independent marker of arteriovascular disease and lowering plasma tHcy concentrations decreases that risk, the measurement of plasma tHcy may become routine in hospital laboratories.
Current assays for plasma tHcy initially reduce the protein-bound and disulphide states of homocysteine into forms that can be measured directly or postderivatization. Common methodologies include highperformance liquid chromatography (HPLC), 3 gas chromatography (GC) 4 and immunoassay. 5 The HPLC and GC methods are generally time-consuming and require specialized equipment, whereas immunoassays are convenient but reagent costs are higher. With the increasing availability of liquid chromatography-tandem mass spectrometry (LC -MS/ MS) in clinical laboratories and the potential requirement for screening large numbers of subjects for hyperhomocysteinaemia, there is a requirement for a validated high-throughput LC -MS/MS method for measuring tHcy. Such a method has previously been described. 6 A problematic step in plasma tHcy analysis is sample collection, as plasma specimens require to be separated from cells within 15 min to prevent artefactual increases in plasma concentrations.
The aim of the study was to develop and validate reliable, rapid and simple methods using LC -MS/ MS for the measurement of tHcy in plasma and dried blood spots that are suitable for routine use. In addition, the feasibility of measuring tHcy in dried blood spots as an alternative to plasma was explored to determine whether the results from the analysis of the dried blood spot could be used to predict the plasma concentration.
Methods

Patients' samples
Ethical approval was received from the hospital's ethical committee. An additional EDTA sample was collected from heart transplant patients attending the outpatients clinic. Heart transplant patients were selected as it has been well documented that mild hyperhomocysteinaemia occurs in this group, 7 thus ensuring that a wide range of homocysteine values were obtained. A blood spot (on Standardized Scheilder & Scheull 903 ¢lter paper) was produced 5-20 min after the sample was drawn; the remaining specimen was then centrifuged immediately and the plasma separated and stored at 7208C until analysis.
Chemicals
HPLC-grade methanol was obtained from Merck (Poole, UK). Dithiothreitol, formic acid, tri£uoracetic acid and homocysteine were obtained from Sigma-Aldrich (Gillingham, UK). Homocystine-d 8 was obtained from Cambridge Isotope Laboratories (Hertfordshire, UK).
Liquid chromatography-tandem mass spectrometry
A Quattro micro tandem mass spectrometer (Micromass, Altrinchham, UK) ¢tted with a Z-Spray ion source coupled to a Waters 2790 Alliance HT HPLC system was used. The column was aWaters Symmetry C8 (2.16100 mm). The mobile phase was 30% aqueous methanol containing 0.1% formic acid at a £ow rate of 0.25 mL/min. The system was operated and data acquired using MassLynx NT v3.5 software.
Optimization of analytical conditions
A homocysteine stock solution was prepared in 20 mmol/ L HCl; from this a 10-mmol/L standard was made in the mobile phase. This standard was used to optimize the LC -MS/MS analysis. The optimum cone voltage to maximize the intensity of the [M + H] + precursor (parent) ion (m/z 136) was 15 V. The collision energy to produce the optimium signal of the most abundant daughter ion (m/z 90) using argon as the collision gas at 5¢0610 73 bar was 15 eV. The product ion spectrum of homocysteine using these parameters is shown in Fig. 1 . The process was repeated for a 10-mmol/L homocysteine-d 4 analogue standard monitoring the m/z transition 140 to 90. The same parameters were optimal for the homocystine-d 8 internal standard.
Standardization
Plasma containing endogenous homocysteine was spiked with homocysteine to produce standards in the range 5-50 mmol/L. tHcy was measured in the plasma-based standards and the slope and positive intercept were calculated using QuanLynx software. The tHcy values were corrected for endogenous tHcy and used as a standard curve.
The standard curve for dried blood spots was made by spiking a fresh (520 min old) whole blood sample to produce standards over the range 5-50 mmol/L. The preparation time of the standards, including spotting, was about 10 min. The tHcy-spiked dried blood spot standards were corrected for endogenous tHcy using a non-tHcy-spiked dried blood spot blank prior to creating the standard curve.
Analysis of plasma samples
For plasma tHcy LC -MS/MS analysis, 10 mL of sample was transferred to a microtitre well, followed by 10 mL of 10 mmol/L homocystine-d 8 internal standard in mobile phase and mixed for 1 min. Then 20 mL of reducing agent (500 mmol/ L dithiothreitol) were added, followed by 100 mL of water containing 0.1% (w/v) formic acid and 0¢025% (w/v) tri£uoroacetic acid, and mixed for 1min. The microtitre plate was placed in the autosampler and 4 mL of supernatant was sampled for analysis.
Analysis of blood spots
The dried blood spot extraction method was adapted from that of Gempel et al. 8 A disc 3 mm in diameter was punched from the dried blood spot and extracted by mixing for 1min with 20 mL of 10 mmol/L homocystine -d 8 internal standard. Then 20 mL of 500 mmol/ L dithiothreitol were added, followed by 100 mL of water containing 0¢1% (w/v) formic acid and 0¢025% (w/v) tri£uoroacetic acid and mixed for 1 min. The microtitre plate was centrifuged for 2 min before 4 mL of supernatant were analysed. The time between injections on the LC -MS/ MS system was less than 2 min.
Measurement of plasma tHcy by immunoassay
The Abbott homocysteine IMx 1 method (Abbott Diagnostics, Chicago, IL, USA) has been described previously 5 and was operated on the Abbott IMx analyser as described in the kit insert.
Statistical analysis
Statistical analysis was carried out using Analyse-It software (University of Leeds, UK). Method comparisons included using a paired t-test, regression lines calculated according to the procedures of Passing and Pablok 9 and agreement assessed according to the Bland-Altman method. 10
Results
Analysis of plasma samples
The regression equation for the LC -MS/MS plasma homocysteine ¢ve-point standard curve (corrected for background blank) was: standard/internal stan-dard=32¢21610 73 6concentration (r 2 =0¢9951). The plasma LC -MS/MS method compared well with the IMx method: plasma LC -MS/MS=1¢18IMx70¢44 (r 2 =0¢915). A Bland-Altman di¡erence plot is shown in Fig. 2 , from which it can be seen that the LC -MS/ MS results were on average 2¢3 mmol/ L higher than the IMx results [standard deviation (SD)=1¢6]; the di¡erences appear to be greater at higher concentrations. The apparent discrepancy in calibration was con¢rmed by measuring the in-house standards on the IMx. The regression line for weighed-in values against the values determined on the IMx was: LC -MS/MS=1¢12IMx + 0¢88, which is consistent with the bias observed on the patients' samples. The withinbatch precision (n=10) of the LC -MS/MS method for plasma was 52.0% at tHcy concentrations of 14¢6 and 37¢7 mmol/L; the between-batch precision (n=10) was 5¢0 and 8¢0%, respectively, at these concentrations. Serial dilution of a high concentration standard showed that the method is linear and sensitive from 
Analysis of blood spots
The regression equation for the ¢ve-point standard curve for the LC -MS/MS dried blood spot homocysteine measurement (corrected for background blank) was: standard/internal standard=0¢146 concentration (r 2 =0¢9989). The extracted blood spot LC -MS/MS and plasma IMx equation was: dried blood spot LC -MS/ MS=0¢33IMx + 1¢77 (r 2 =0¢682). A Bland-Altman di¡erence plot is shown in Fig. 3 , from which it can be seen that the dried blood spot LC -MS/ MS results were on average 8¢89 mmol/L lower than the plasma IMx results (SD=2¢77), the di¡erences appearing to be greater at higher concentrations. A paired t-test showed that the results were signi¢cantly di¡erent (P50¢0001). The within-batch precision (n=10) of the dried blood spot LC -MS/MS method was 7¢3% and 4¢7% at tHcy concentrations of 4¢0 and 7¢9 mmol/L, respectively; the between-batch precision, carried out over 3 months, was 12¢6% and 7¢9% at concentrations of 5¢1 and 8¢0 mmol/L, respectively. To assess whether dried blood spots are suitable as a screening test to detect raised plasma tHcy, arbitrary cut-o¡ levels were compared. If it is assumed that a plasma tHcy concentration of 415 mmol/L represents an increased concentration, 11 a corresponding dried blood spot result of 46 ¢8 mmol/L would have a sensitivity and speci¢city in detecting a raised plasma tHcy concentration of 83¢3% and 96¢2%, respectively. This equates to a positive and negative predictive value of 95% and 86%, respectively, with an e¤ciency of 90%. A dried blood spot cut-o¡ concentration of 6¢2 mmol/L for predicting high plasma tHcy concentrations (415 mmol/L) has a sensitivity and speci¢city of 95¢8% and 73¢1%, respectively, a positive and negative predictive value of 76% and 95%, respectively, and an e¤ciency of 84%. The 6¢8 and 6¢2 mmol/L dried blood spot cut-o¡ concentrations have false negative rates of 17% and 4%, respectively, for predicting a plasma tHcy concentration of 415 mmol/ L.
Conclusion
We have developed and validated a reliable, rapid and simple method to measure plasma tHcy concentration by LC -MS/MS which uses a homocystine-d 8 internal standard and requires no derivatization or centrifugation. The method uses a small sample volume, is rapid (54 min per sample, including preparation time) and is therefore suitable for high-throughput and routine clinical use. There is a concentration-dependent bias between the LC -MS/MS and IMx methods (see Fig. 2 ) as the in-house standards prepared to calibrate the LC -MS/ MS instrument gave higher results, increasing at higher concentrations relative to the IMx. The range of results obtained for the heart transplant patients using the LC -MS/MS method (11¢2-32¢7 mmol/L) are similar to previous results obtained for this group of patients (6¢0 -36¢9 mmol/L). 7 We have also developed a reliable, rapid and simple dried blood spot LC -MS/MS method for tHcy measurement that gave acceptable sample precision and stability over a 3-month period. The potentially high-throughput analysis of dried ¢ngerprick blood spot samples posted to the laboratory could be used as a screening test for hyperhomocysteinaemia, obviating the problems associated with plasma sampling. Measured dried blood spot tHcy concentrations are considerably lower than plasma tHcy concentrations (P50¢0001), probably because the concentration of homocysteine in red blood cells is low. Using a dried blood spot cut-o¡ of 6¢8 mmol/L correctly predicts a plasma result greater or lower than 15 mmol/L with a 90% e¤ciency. However, this cut-o¡ concentration has false positive and false negative rates of 4% and 17%, respectively. False positive results could be correctly reclassi¢ed with a follow-up plasma tHcy measurement; however, 17% of hyperhomocysteinaemic patients would be missed. A lower cut-o¡ of 6¢2 mmol/L, while having less overall e¤ciency and speci¢city (84% and 73%, respectively), would result in only 4% of hyperhomocysteinaemic patients being missed; however, the false positive rate would be 27%.
In conclusion, dried blood spot tHcy measurements may be useful for screening for hyperhomocysteinaemia, allowing the selection of patients who require plasma testing. The dried blood spot cut-o¡ concentration used to select those patients requiring further plasma testing would have to be selected on the basis of acceptable false positive and false negative results.
